Quant Biomarkers aims to revolutionize cardio-renal and metabolic health with AI-driven solutions and novel biomarkers. We are at the forefront of precision medicine and our goal is to integrate our products into routine clinical workflows spanning primary and speciality care and clinical trials.
Products, services, technology
Building on robust data across mice, dogs, humans, and nine common nephropathies, we are developing RenoRisk Detect, a novel urine-based biomarker panel, and RenoPredict, an AI/ML-based clinical decision support system for early CKD detection, risk and patient stratification, and clinical trials.
Cooperation possibilities
Biomarker platforms, CDx and Dx discovery, development, optimisation, technology switches and validation, from pre-clinical to market robust biomarkers. Hospital care focused on Chronic Kidney Disease, CardioRenal and Metabolic Syndrome.
- http://www.quant-biomarkers.swiss
- Send an email
- Sanja Tomovska
Some insights
Quant Biomarkers AG. contributes to making the world a better place through its focus on advancing healthcare with innovative solutions. With a specific emphasis on Kidney Health and early detection of CKD, we strive to improve health outcomes & enhance the quality of life for individuals worldwide.
We are proud of our commitment to early chronic diaseses detection. Innovative solutions for therapeutic advancement, leveraging cutting-edge technologies, mpact on aging populations & contributing to global health, effective clinical decisions, improving and extending lives & cut healthcare costs.
Everyone that inspire us to push boundaries, embrace innovation, and contribute meaningfully to the advancement of biotechnology for the benefit of society.
Platform technologies, Biomarkers, R&D, Dignostics, Partnering and collaborations,
Helping people to stay healthy and happy.
Helping create a supportive environment to connect with key stakeholders.
Hospital platforms, AI/ML partners, pharmaceutical companies, insurers, and diagnostic labs.